Welcome to our dedicated page for Praxis Precision Medicines SEC filings (Ticker: PRAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Praxis Precision Medicines filings document regulatory disclosures for a CNS-focused biopharmaceutical issuer with common stock listed on the Nasdaq Global Select Market under PRAX. Its Form 8-K and 8-K/A reports cover material events, operating and financial results, clinical and regulatory updates, capital-structure disclosures, and leadership or board changes.
The company’s filing record includes disclosures related to ulixacaltamide HCl for essential tremor, elsunersen in SCN2A developmental and epileptic encephalopathy, and broader pipeline programs in movement disorders and epilepsy. Proxy materials address annual meeting matters, board composition, committee assignments, executive compensation, equity awards and other governance subjects.
Praxis Precision Medicines director Stuart A. Arbuckle reported equity compensation awards. He received 1,371 restricted stock units, each representing a contingent right to one share of common stock, vesting in a single installment on the earlier of June 10, 2027 or the company’s 2027 annual stockholder meeting. He was also granted options to purchase 648 shares of common stock at an exercise price of $240.66 per share, vesting in twelve equal monthly installments beginning July 10, 2026 and ending on the earlier of June 10, 2027 or the 2027 annual meeting. After these awards, he directly holds 2,537 common shares and 648 stock options, reflecting routine director compensation rather than open-market buying.
Praxis Precision Medicines director Jeffrey Chodakewitz received new equity awards as part of his compensation. He was granted 1,371 restricted stock units, each representing the right to receive one share of common stock, vesting in a single installment on the earlier of June 10, 2027 or the company’s 2027 annual stockholder meeting. He also received options for 648 shares at an exercise price of $240.66 per share, vesting in twelve equal monthly installments starting July 10, 2026 and expiring on June 10, 2036. These are awards from the company, not open-market purchases or sales.
Praxis Precision Medicines director William D. Young received new equity awards. On June 10, 2026, he was granted 1,371 restricted stock units, each representing one future share of common stock, vesting in a single installment on the earlier of June 10, 2027 or the 2027 annual stockholders meeting.
He was also granted a stock option for 648 shares of common stock at an exercise price of $240.6600 per share, vesting in twelve equal monthly installments beginning July 10, 2026 through the earlier of June 10, 2027 or the 2027 annual meeting. Following these awards, he directly owns 3,269 common shares and holds options for 648 shares.
Praxis Precision Medicines director Jill DeSimone received new equity awards as part of her compensation. She was granted 1,371 restricted stock units, each representing a right to receive one share of common stock, vesting in a single installment on the earlier of June 10, 2027 or the company’s 2027 annual stockholders meeting.
She also received a stock option for 648 shares of common stock at an exercise price of $240.66 per share, vesting in twelve equal monthly installments beginning July 10, 2026 and ending on the earlier of June 10, 2027 or the 2027 annual meeting. After these grants, she directly holds 2,337 shares of common stock and 648 stock options.
Praxis Precision Medicines director Merit Ester Cudkowicz reported equity compensation awards. She received 1,371 restricted stock units, each representing one future share of common stock. These units vest in a single installment on the earlier of June 10, 2027 or the company’s 2027 annual stockholder meeting and are settled only in shares.
She was also granted an option to buy 648 shares of common stock at an exercise price of $240.66 per share. The option vests in 12 equal monthly installments beginning July 10, 2026, with final vesting on the earlier of June 10, 2027 or the 2027 annual meeting. Following these grants, she reports 1,371 common shares and 648 options as directly owned.
Praxis Precision Medicines director J. Dean Mitchell received equity awards as part of his compensation. He was granted 1,371 restricted stock units, each representing a right to receive one share of common stock, vesting in a single installment on the earlier of June 10, 2027 or the 2027 annual stockholder meeting.
Mitchell was also granted stock options for 648 shares of common stock at an exercise price of $240.66 per share, vesting in twelve equal monthly installments starting July 10, 2026 and ending on the earlier of June 10, 2027 or the 2027 annual meeting. Following these awards, he directly holds 18,622 common shares.
Praxis Precision Medicines director Jeffrey B. Kindler reported equity awards consisting of restricted stock units and stock options. He was granted 1,371 restricted stock units, each representing a right to receive one share of common stock, bringing his reported common stock holdings to 2,537 shares after the award.
These restricted stock units vest in a single installment on the earlier of June 10, 2027 or the company’s 2027 annual stockholder meeting and will be settled in shares. Kindler was also granted options for 648 shares of common stock at an exercise price of $240.66 per share, vesting in twelve equal monthly installments starting July 10, 2026 through the earlier of June 10, 2027 or the 2027 annual meeting. The filing reflects routine director compensation grants rather than open‑market buying or selling.
Praxis Precision Medicines director Gregory Norden reported equity awards consisting of restricted stock units and stock options. He was granted 1,371 restricted stock units, each representing a contingent right to receive one share of common stock. These units vest in a single installment on the earlier of June 10, 2027 or the company’s 2027 annual stockholder meeting.
In a separate award, Norden received options to buy 648 shares of common stock at an exercise price of $240.66 per share. These options vest in twelve equal monthly installments starting on July 10, 2026, with the final installment on the earlier of June 10, 2027 or the 2027 annual meeting. Following the reported grants, he holds 1,559 common shares directly and 648 options, reflecting routine director compensation rather than open-market trading.
Praxis Precision Medicines, Inc. reported results of its 2026 Annual Meeting of Stockholders held on June 10, 2026. Stockholders elected three Class III directors — Gregory Norden, Marcio Souza and William Young — to serve until the 2029 annual meeting, with each receiving more than 21 million votes in favor.
Stockholders also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 26,667,376 votes for and limited opposition. In an advisory, non-binding vote, stockholders approved the compensation of the company’s named executive officers, with 24,054,017 votes for and 824,318 against. No other matters were submitted for a vote.
Praxis Precision Medicines reported clinical trial results for vormatrigine in patients with focal onset seizures. In the Phase 2/3 POWER1 study in highly refractory patients, vormatrigine did not meet the primary success measure, which is a setback for this program. A key secondary measure, the 50% response rate, was met, and seizure reduction in the second half of the study at the higher 30 mg dose was more pronounced, suggesting some dose-related benefit. Vormatrigine was generally well tolerated, with adverse event-related discontinuations under 10%, and about 90% of patients from the vormatrigine arm moved into and remain in the open-label extension. The company is pausing enrollment in the POWER2 study while it reassesses the vormatrigine program and considers potential modifications.